Listen and subscribe to open the offer Apple Podcasts., Spotify., YouTubeOr wherever you find your favorite podcasts.
After making $ 300 billion in health deals for several decades, there is one Bausch and Lomb (BlCO) transaction chairman and CEO Brent Saunders will not conclude in 2025.
The one for his manufacturer of contact lenses with a history dating from the 1800s.
“No, I doubt [if we restart the deal process]”Saunders told me about the initial podcast of Yahoo Finance’s offer (video above; listen below).” You can never say, but, look, we have a great ambitious plan for 2025 and honestly, as I look at 2026 and 2027, it’s even a bolder plan. And so we head down and focus on the work of the business and the achievement of the best results we can. “
Bausch and Lomb said earlier this month that they had investigated the company’s acceptance privately with a third-party buyer. A transaction was not achieved as a consortium of private capital companies, including TPG (TPG) and Blackstone (BX), has been reported to have retreated. Bausch and Lomb said he would not pursue a transaction at this time.
But she reiterated that the goal was a complete separation with Bausch’s health companies. Bausch Health Company owns 88.4% of Bausch and Lomb.
Saunders believes that interested buyers have underestimated the company’s product pipeline, which includes new contact lens technologies, dry eye relief and surgical products.
“There is always skepticism in research and development and I expect it. But there was definitely a deeper discount attributed to our pipeline for research and development, whether in pharmaceutical or contact lenses or surgery or even users,” Saunders explained.
Saunders has been known as one of the largest deals in the pharmaceutical industry in the last 15 years.
In May 2013, during his first execution as CEO of Bausch and Lomb, he organized his sale at $ 8.7 billion to Valeant Pharmaceuticals.
He then took over as CEO of Forest Laboratories.
Until February 2014, Saunders organized the sale of Actavis for $ 25 billion. He took the position of the Executive Director.
From there, in November 2014, he pulled out $ 70 billion in acquisition of Allergan and became its CEO.
It was there that Saunders star quickly rose to media circles, watching Botox’s trade success and fighting with fear of activist Carl Ikan’s investor.
Then Saunders sold Allergan to Abbvie (ABBV) for $ 63 billion in a deal that closed in May 2020. He returned to Baus and Lomb as CEO in March 2023.
Today, Ikan Brett’s son is sitting aboard Bausch and Lomb along with Hedge Fund Titan John Pales and Sonders.